Skip to main content
Full access
Letter to the Editor
Published Online: 1 April 1999

Chronic Psychotic Illness From Methamphetamine

Publication: American Journal of Psychiatry
To the Editor: In the past decade, methamphetamine abuse has been on the rise throughout the United States (1, 2). Although methamphetamine is generally taken orally or intravenously, crystal methamphetamine or “ice” is smoked. This manner of admission is highly addictive. It is odorless, difficult to detect, and less expensive and longer lasting than crack. Vaporized crystal methamphetamine, when inhaled, is rapidly absorbed through lung capillaries and has pharmacokinetics similar to intravenous amphetamines. With continued abuse, crystal methamphetamine usually leads to paranoid, often violent, psychotic states accompanied by auditory and tactile hallucinations. Many, but not all, patients improve with abstinence and symptomatic treatment with low-dose neuroleptics. Brain damage to dopamine and 5-hydroxytryptamine receptors from the vasoconstriction and neurotoxicity of methamphetamine has been documented in animals (3). Our experience in Hawaii has provided some clinical evidence to support this.
While binding sites and cerebral perfusion deficits resulting from cocaine and crack abuse have been mapped out with single photon emission computed tomography (SPECT), identifying focal and long-term perfusion deficits in frontal and temporal lobes (46), no known study of cerebral perfusion in crystal methamphetamine abusers has been published to date. To assess brain perfusion deficits in crystal methamphetamine abusers, we used SPECT to scan 21 crystal methamphetamine abusers with psychotic symptoms. Scans were read by qualified neuroradiologists who were blind to the diagnoses. Length of crystal methamphetamine abuse ranged from 3 months to 10 years. No patients’ charts showed a history of psychotic diagnosis or symptoms before the use of crystal methamphetamine. Sixteen of the 21 (76%) crystal methamphetamine abusers had focal perfusion deficits distributed in the frontal, parietal, and temporal lobes. A similar cerebral perfusion profile has been described for those who exhibit violent or aggressive behavior (7). Although our study group size was small, dose and length of exposure appear to be related to the extent of the perfusion deficits. In a few additional crystal methamphetamine abusers with psychotic symptoms, multiple SPECT scans have been done to document deficits over time—even years after crystal methamphetamine has left their bodies.
The “ice age” in Hawaii has shown methamphetamine abuse to be both debilitating and dangerous. Our preliminary findings suggest that crystal methamphetamine abuse leads to short-term and potentially long-term functional abnormalities linked to violence. Further research is needed. Clinical data and SPECT scans on crystal methamphetamine abusers are now being reviewed.

References

1.
Office of National Drug Control Policy. Methamphetamine: Facts and Figures. Rockville, Md, Office of National Drug Control Policy, 1997
2.
Baberg HT, Nelesen RA, Dimsdale JE: Amphetamine use: return of an old scourge in a consultation psychiatry setting. Am J Psychiatry 1996; 153:789–793
3.
Seiden LS: Neurotoxicity of methamphetamine: mechanisms of action and issues related to aging. National Institute on Drug Abuse Research Monograph Series 1991; 115:72–83
4.
Holman BL, Carvalho PA, Mendelson J, Teoh SK, Nardin R, Hall­gring E, Hebben N, Johnson KA: Brain perfusion is abnormal in cocaine-dependent polydrug users: a study using technetium-99m-HMPAO and SPECT. J Nucl Med 1991; 32:1206–1210
5.
Weber DA, Fanceschi D, Ivanovic M, Atkins HL, Cabahug C, Wong CTC, Susskind H: SPECT and planar brain imaging in crack abuse: iodine-123-iodoamphetamine uptake and localization. J Nucl Med 1993; 34:899–907
6.
Volkow HD, Hitzemann R, Wang GJ, Fowler JS: Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992; 11:184–190
7.
Amen DG, Stubblefield M, Carmichael B, Thisted R: Brain SPECT findings and aggressiveness. Ann Clin Psychiatry 1996; 8:129–137

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 662
PubMed: 10200757

History

Published online: 1 April 1999
Published in print: April 1999

Authors

Affiliations

ALAN BUFFENSTEIN, M.D.
PETER KO, M.D.
Honolulu, Hawaii

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share